Etomidate
- Etomidate ETOMIDATE 2 mg/mL Mylan Institutional LLC
- Amidate ETOMIDATE 2 mg/mL Henry Schein, Inc.
- Amidate ETOMIDATE 2 mg/mL Hospira, Inc.
- Etomidate ETOMIDATE 2 mg/mL Zydus Lifesciences Limited
- Etomidate ETOMIDATE 2 mg/mL Mylan Institutional LLC
- Etomidate ETOMIDATE 2 mg/mL Fresenius Kabi USA, LLC
- Etomidate ETOMIDATE 2 mg/mL Sagent Pharmaceuticals
- Etomidate ETOMIDATE 2 mg/mL Fresenius Kabi USA, LLC
- Etomidate ETOMIDATE 2 mg/mL Fresenius Kabi USA, LLC
- Etomidate ETOMIDATE 2 mg/mL Armas Pharmaceuticals Inc.
- Etomidate ETOMIDATE 2 mg/mL Zydus Pharmaceuticals USA Inc.
- Etomidate ETOMIDATE 2 mg/mL Armas Pharmaceuticals Inc.
- AMIDATE(TM) ETOMIDATE ETOMIDATE 2 mg/mL HF Acquisition Co LLC, DBA HealthFirst
Summary of product characteristics
Effective Time
20221017
Version
5
Spl Product Data Elements
etomidate etomidate ETOMIDATE ETOMIDATE PROPYLENE GLYCOL
Application Number
ANDA202360
Brand Name
Etomidate
Generic Name
etomidate
Product Ndc
65841-818
Product Type
HUMAN PRESCRIPTION DRUG
Route
INTRAVENOUS
Package Label Principal Display Panel
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Vial Label 10 mL Zydus Pharmaceuticals NDC 65841-818-07 Etomidate Injection, USP 20 mg/10 mL (2 mg/mL) For Intravenous Use 10 mL, Single-Dose Vial Rx Only Carton Label 10 mL Zydus Pharmaceuticals NDC 65841-818-07 Etomidate injection, USP 20 mg/10 mL (2 mg/mL) For Intravenous Use 10 x 10 mL, Single-Dose Vials Rx Only Vial Label 20 mL Zydus Pharmaceuticals NDC 65841-818-08 Etomidate injection, USP 40 mg/20 mL (2 mg/mL) For Intravenous Use 20 mL, Single-Dose Vial Rx Only Carton Label 20 mL Zydus Pharmaceuticals NDC 65841-818-08 Etomidate injection, USP 40 mg/20 mL (2 mg/mL) For Intravenous Use 10 x 20 mL, Single-Dose Vials Rx Only figure02 figure03 figure04 figure05
Drug section
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.